Orexo Announces Positive Phase III Results For KW-2246 In Japan

Orexo’s (STO:ORX) partner in Japan, Kyowa Hakko Kirin, has obtained positive phase III results in Japan for KW-2246, which is approved for the treatment of breakthrough pain in cancer patients and marketed under the brand AbstralTM in Europe. Kyowa Hakko Kirin will now proceed with preparations for a new-drug application for KW-2246 in Japan for use in continuous pain management of acute cancer pain (breakthrough pain).

More: continued here

Filed under: Pain / Anesthetics on August 10th, 2009